Twenty Two Bio
Twenty Two Bio provides biosurveillance and AI biosecurity solutions for the AI era, operating a wastewater metagenomic monitoring network across 27 U.S. sites covering 13M+ people. The company also offers dual-use screening aligned with the EU Biotech Act and US executive orders, plus AI biosecurity evaluations adopted by frontier AI labs.
- Biotechnology
- Artificial Intelligence
- Data & Analytics
- Healthcare Technology
- Regulatory & Compliance Technology
- Government Technology
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
The bioeconomy is scaling rapidly—DNA synthesis costs have dropped 99% in two decades and cloud labs make experiments as routine as an API call—yet biosecurity infrastructure has not kept pace. This widening gap creates unmanaged risks of accidental or deliberate misuse of biological technologies, even as new regulations mandate security measures.
Solution
Twenty Two Bio provides biosurveillance and AI biosecurity solutions purpose-built for the AI era. The platform operates a nationwide wastewater metagenomic monitoring network spanning 27 U.S. sites covering 13M+ people, detecting emerging biological threats before they spread. Complementing this physical surveillance, the company offers dual-use screening aligned with the EU Biotech Act and US executive orders, helping organizations comply with mandatory security regulations. The company's AI biosecurity evaluations have been adopted by frontier AI labs, and its proprietary machine learning methods predict viral evolution, enabling proactive defense rather than reactive response.
Target Audience
Primary customers include government agencies and public health organizations requiring biosurveillance, as well as synthetic biology companies, cloud labs, and AI labs that need dual-use screening compliance and biosecurity evaluations.
Features
- Wastewater metagenomic surveillance network across 27 U.S. sites monitoring populations of 13M+ people
- Deep untargeted wastewater metagenomic sequencing methods for broad-spectrum pathogen detection, including SARS-CoV-2, influenza, and avian influenza H5N1
- Dual-use screening aligned with EU Biotech Act and US executive order requirements
- AI biosecurity evaluation frameworks adopted by frontier AI labs
- Machine learning methods for predicting viral evolution and anticipating emerging variants
- Automated customer screening combining AI agents with traditional data sources for background intelligence gathering with complete audit trails
- Peer-reviewed research published across leading academic and scientific venues, including medRxiv